Santhera’s MICONOS Trial with Catena in Friedreich’s Ataxia Misses Primary Endpoint

Press Release Liestal, Switzerland, May 20, 2010 – Santhera Pharmaceuticals (SIX: SANN) announced today that its MICONOS Phase III study evaluating Catena®/Sovrima® for the treatment of Friedreich’s Ataxia missed its primary endpoint. Trends towards improvement in the key neurological endpoint were however identified by a meta-analysis of all Santhera’s Phase...

Continue reading

Additional documents on Catena (Idebenon)

Some relevant information about Catena® (Idebenon) Catena®: Fact Sheet Catena®(idebenone): Product Monograph Catena®(idebenone): Product Monograph. Part III Actual Payer Coverage in Canada for CATENA® (Idebenon) Santhera Pharmaceuticals about preliminary results of the CATENA US clinical trial

Continue reading

Health Canada Approves Catena® for Treatment of Friedreich’s Ataxia

News Release Liestal, Switzerland, July 24, 2008 – Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today that Health Canada has approved with conditions SNT-MC17/idebenone for the treatment of Friedreich’s Ataxia. Health Canada’s decision is the first marketing authorization worldwide for any Friedreich’s Ataxia therapy....

Continue reading

Cardiac problems in Friedreich’s Ataxia

Around 90% of patients afflicted with Friedreich’s Ataxia (FA) eventually show cardiac symptoms. In general, ataxia precedes the beginning of the cardiac symptoms. With most patients, it involves a cardiac disease called left ventricular hypertrophy. Left ventricular hypertrophy is an increase in the thickness of the wall and of the...

Continue reading